CNS Drugs
Journal Impact IF - Analysis · Trend · Prediction · Ranking


New

Journal Impact IF

2019-2020

4.786

14.2%

Journal Impact IF Trend

Related Journals

Popular Journals

CNS Drugs

The 2019-2020 Journal Impact IF of CNS Drugs is 4.786, which is just updated in 2020.

CNS Drugs Impact Factor
Highest IF
5.113
Highest Journal Impact IF

The highest Journal Impact IF of CNS Drugs is 5.113.

Lowest IF
4.192
Lowest Journal Impact IF

The lowest Journal Impact IF of CNS Drugs is 4.192.

Total Growth Rate
-0.2%
IF Total Growth Rate

The total growth rate of CNS Drugs IF is -0.2%.

Annual Growth Rate
-0.0%
IF Annual Growth Rate

The annual growth rate of CNS Drugs IF is -0.0%.

Journal Impact IF Ranking

Subcategory Quartile Rank Percentile
Pharmacology (medical) Q1 17/237

Pharmacology (medical) 93%

Neurology (clinical) Q1 34/348

Neurology (clinical) 90%

Psychiatry and Mental Health Q1 30/506

Psychiatry and Mental Health 94%

Journal Impact IF Ranking

· In the Pharmacology (medical) research field, the Quartile of CNS Drugs is Q1. CNS Drugs has been ranked #17 over 237 related journals in the Pharmacology (medical) research category. The ranking percentile of CNS Drugs is around 93% in the field of Pharmacology (medical).
· In the Neurology (clinical) research field, the Quartile of CNS Drugs is Q1. CNS Drugs has been ranked #34 over 348 related journals in the Neurology (clinical) research category. The ranking percentile of CNS Drugs is around 90% in the field of Neurology (clinical).
· In the Psychiatry and Mental Health research field, the Quartile of CNS Drugs is Q1. CNS Drugs has been ranked #30 over 506 related journals in the Psychiatry and Mental Health research category. The ranking percentile of CNS Drugs is around 94% in the field of Psychiatry and Mental Health.

CNS Drugs Impact Factor 2020-2021 Prediction

CNS Drugs Impact Factor Predition System

CNS Drugs Impact Factor Prediction System is now online. You can start share your valuable insights with the community.

Predict Check All Preditions
Total Publications
2359
Total Citations
107003

Annual Publication Volume

Annual Citation Record

International Collaboration Trend

Cited Documents Trend

Journal Impact IF History

Year Journal Impact IF
Year Journal Impact IF
2019-2020 4.786
2018-2019 4.192
2017-2018 4.206
2016-2017 4.394
2015-2016 4.91
2014-2015 5.113
2013-2014 4.376
2012-2013 4.826
2011-2012 4.795
Journal Impact IF History

· The 2019-2020 Journal Impact IF of CNS Drugs is 4.786
· The 2018-2019 Journal Impact IF of CNS Drugs is 4.192
· The 2017-2018 Journal Impact IF of CNS Drugs is 4.206
· The 2016-2017 Journal Impact IF of CNS Drugs is 4.394
· The 2015-2016 Journal Impact IF of CNS Drugs is 4.91
· The 2014-2015 Journal Impact IF of CNS Drugs is 5.113
· The 2013-2014 Journal Impact IF of CNS Drugs is 4.376
· The 2012-2013 Journal Impact IF of CNS Drugs is 4.826
· The 2011-2012 Journal Impact IF of CNS Drugs is 4.795

Publications Cites Dataset

Year Publications Citations
Year Publications Citations
1993 0 1
1994 86 34
1995 88 161
1996 78 297
1997 79 529
1998 86 672
1999 83 754
2000 70 947
2001 72 898
2002 78 1263
2003 77 1778
2004 101 2308
2005 94 2988
2006 103 3793
2007 87 4054
2008 76 4730
2009 86 4986
2010 74 5593
2011 83 6276
2012 124 7098
2013 102 7122
2014 92 7817
2015 82 7634
2016 89 7263
2017 86 7145
2018 98 5768
2019 92 6434
2020 90 7932
2021 3 728
Publications Cites Dataset

· The CNS Drugs has published 0 reports and received 1 citations in 1993.
· The CNS Drugs has published 86 reports and received 34 citations in 1994.
· The CNS Drugs has published 88 reports and received 161 citations in 1995.
· The CNS Drugs has published 78 reports and received 297 citations in 1996.
· The CNS Drugs has published 79 reports and received 529 citations in 1997.
· The CNS Drugs has published 86 reports and received 672 citations in 1998.
· The CNS Drugs has published 83 reports and received 754 citations in 1999.
· The CNS Drugs has published 70 reports and received 947 citations in 2000.
· The CNS Drugs has published 72 reports and received 898 citations in 2001.
· The CNS Drugs has published 78 reports and received 1263 citations in 2002.
· The CNS Drugs has published 77 reports and received 1778 citations in 2003.
· The CNS Drugs has published 101 reports and received 2308 citations in 2004.
· The CNS Drugs has published 94 reports and received 2988 citations in 2005.
· The CNS Drugs has published 103 reports and received 3793 citations in 2006.
· The CNS Drugs has published 87 reports and received 4054 citations in 2007.
· The CNS Drugs has published 76 reports and received 4730 citations in 2008.
· The CNS Drugs has published 86 reports and received 4986 citations in 2009.
· The CNS Drugs has published 74 reports and received 5593 citations in 2010.
· The CNS Drugs has published 83 reports and received 6276 citations in 2011.
· The CNS Drugs has published 124 reports and received 7098 citations in 2012.
· The CNS Drugs has published 102 reports and received 7122 citations in 2013.
· The CNS Drugs has published 92 reports and received 7817 citations in 2014.
· The CNS Drugs has published 82 reports and received 7634 citations in 2015.
· The CNS Drugs has published 89 reports and received 7263 citations in 2016.
· The CNS Drugs has published 86 reports and received 7145 citations in 2017.
· The CNS Drugs has published 98 reports and received 5768 citations in 2018.
· The CNS Drugs has published 92 reports and received 6434 citations in 2019.
· The CNS Drugs has published 90 reports and received 7932 citations in 2020.
· The CNS Drugs has published 3 reports and received 728 citations in 2021.
· The total publications of CNS Drugs is 2359.
· The total citations of CNS Drugs is 107003.

What is Impact Factor?

The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly average number of citations of articles published in the last two years in a given journal. It is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factor values are often deemed to be more important, or carry more intrinsic prestige in their respective fields, than those with lower values.

CNS Drugs | Academic Accelerator - About the Impact Factor

Impact factor is commonly used to evaluate the relative importance of a journal within its field and to measure the frequency with which the “average article” in a journal has been cited in a particular time period. Journal which publishes more review articles will get highest IFs. Journals with higher IFs believed to be more important than those with lower ones. According to Eugene Garfield “impact simply reflects the ability of the journals and editors to attract the best paper available.” Journal which publishes more review articles will get maximum IFs. The Impact Factor of an academic journal is a scientometric Metric that reflects the yearly average number of citations that recent articles published in a given journal received. It is frequently used as a Metric for the relative importance of a journal within its field; journals with higher Impact Factor are often deemed to be more important than those with lower ones. The CNS Drugs Impact Factor IF measures the average number of citations received in a particular year (2020) by papers published in the CNS Drugs during the two preceding years (2018-2019). Note that 2020 Impact Factor are reported in 2021; they cannot be calculated until all of the 2020 publications have been processed by the indexing agency. New journals, which are indexed from their first published issue, will receive an impact factor after two years of indexing; in this case, the citations to the year prior to Volume 1, and the number of articles published in the year prior to Volume 1, are known zero values. Journals that are indexed starting with a volume other than the first volume will not get an impact factor until they have been indexed for three years. Occasionally, Journal Citation Reports assigns an impact factor to new journals with less than two years of indexing, based on partial citation data. The calculation always uses two complete and known years of item counts, but for new titles one of the known counts is zero. Annuals and other irregular publications sometimes publish no items in a particular year, affecting the count. The impact factor relates to a specific time period; it is possible to calculate it for any desired period. In addition to the 2-year Impact Factor, the 3-year Impact Factor, 4-year Impact Factor, 5-year Impact Factor, Real-Time Impact Factor can provide further insights and factors into the impact of CNS Drugs.

History

The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI). Impact factors are calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson ISI was sold to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.

Use

The impact factor is used to compare different journals within a certain field. The Web of Science indexes more than 11,500 science and social science journals. Journal impact factors are often used to evaluate the merit of individual articles and individual researchers. This use of impact factors was summarised by Hoeffel:

Impact Factor is not a perfect tool to measure the quality of articles but there is nothing better and it has the advantage of already being in existence and is, therefore, a good technique for scientific evaluation. Experience has shown that in each specialty the best journals are those in which it is most difficult to have an article accepted, and these are the journals that have a high impact factor. Most of these journals existed long before the impact factor was devised. The use of impact factor as a measure of quality is widespread because it fits well with the opinion we have in each field of the best journals in our specialty....In conclusion, prestigious journals publish papers of high level. Therefore, their impact factor is high, and not the contrary.

Eugene Garfield

In brief, Impact factors may be used by:
  • Authors to decide where to submit an article for publication.
  • Libraries to make collection development decisions
  • Academic departments to assess academic productivity
  • Academic departments to make decisions on promotion and tenure.
As impact factors are a journal-level metric, rather than an article- or individual-level metric, this use is controversial. Garfield agrees with Hoeffel,but warns about the "misuse in evaluating individuals" because there is "a wide variation [of citations] from article to article within a single journal". Other things to consider about Impact Factors:
  • Many journals do not have an impact factor.
  • The impact factor cannot assess the quality of individual articles. Even if citations were evenly distributed among articles, the impact factor would only measure the interests of other researchers in an article, not its importance and usefulness.
  • Only research articles, technical notes and reviews are “citable” items. Editorials, letters, news items and meeting abstracts are “non-citable items”.
  • Only a small percentage of articles are highly cited and they are found in a small subset of journals. This small proportion accounts for a large percentage of citations.
  • Controversial papers, such as those based on fraudulent data, may be highly cited, distorting the impact factor of a journal.
  • Citation bias may exist. For example, English language resources may be favoured. Authors may cite their own work.
Moreover, informed and careful use of these impact data is essential, and should be based on a thorough understanding of the methodology used to generate impact factors. There are controversial aspects of using impact factors:
  • It is not clear whether the number of times a paper is cited measures its actual quality.
  • Some databases that calculate impact factors fail to incorporate publications including textbooks, handbooks and reference books.
  • Certain disciplines have low numbers of journals and usage. Therefore, one should only compare journals or researchers within the same discipline.
  • Review articles normally are cited more often and therefore can skew results.
  • Self-citing may also skew results.
  • Some resources used to calculate impact factors have inadequate international coverage.
  • Editorial policies can artificially inflate an impact factor.
Impact factors have often been used in advancement and tenure decision-making. Many recognize that this is a coarse tool for such important decisions, and that a multitude of factors should be taken into account in these deliberations. When considering the use of the impact factor (IF), keep these aspects in mind:
  • IF analysis is limited to citations from the journals indexed by the Web of Science/Web of Knowledge. Currently, the Web of Science indexes only 8621 journals across the full breadth of the sciences, and just 3121 in the social sciences.
  • A high IF/citation rate says nothing about the quality -- or even, validity -- of the references being cited. Notorious or even retracted articles often attract a lot of attention, hence a high number of citations. The notority related to the first publication on "cold fusion" is one such example.
  • Journals that publish more "review articles" are often found near the top of the rankings. While not known for publishing new, creative findings, these individual articles tend to be heavily cited.
  • The IF measures the average number of citations to articles in the journal -- given this, a small number of highly-cited articles will skew the figure.
  • It takes several years for new journals to be added to the list of titles indexed by the Web of Science/Web of Knowledge, so these newer titles will be under-represented.
  • It's alleged that journal editors have learned to "game" the system, encouraging authors to cite their works previously published in the same journal.
Comparing Journals Across Disciplines? Not a good idea! Using Impact Factors within a given discipline should only be done with great care, as described above. Using impact factor data to compare journals across disciplines is even more problematic. Here are some of the reasons:
  • Disciplines where older literature is still referenced, such as Chemistry and Mathematics, offer challenges to the methodolgy since older citations (older than two years) are not used to calculate the impact factor for a given journal. (Five-year impact factor analysis, which can be calculated using the Journal Citation Index database, helps smooth out this problem only to some degree.)
  • Different disciplines have different practices regarding tendency to cite larger numbers of references. Higher overall citation rates will bump upward impact factor measurements.
  • Where it's common for large numbers of authors to collaborate on a single paper, such as in Physics, the tendency of authors to cite themselves (and in this case, more authors) will result in increased citation rates.

Pros and Cons of the Impact Factor

Pros:

  • A vetted, established metric for measuring journal impact within a discipline.
  • Designed to eliminate bias based on journal size and frequency.
Cons:
  • Individual articles makes an uneven contribution to overall Impact Factor.
  • Impact Factor does not account for certain things, things like context (postive or negative citaion) and intentionality (self-citation).
  • The metric is proprietary to and bound by the contents of the Thomson Reuters database.
  • Citations, on which the Impact Factor is based, count for less than 1% of an article's overall use.

Criticism

Numerous critiques have been made regarding the use of impact factors. A 2007 study noted that the most fundamental flaw is that impact factors present the mean of data that are not normally distributed, and suggested that it would be more appropriate to present the median of these data. There is also a more general debate on the validity of the impact factor as a measure of journal importance and the effect of policies that editors may adopt to boost their impact factor (perhaps to the detriment of readers and writers). Other criticism focuses on the effect of the impact factor on behavior of scholars, editors and other stakeholders. Others have made more general criticisms, arguing that emphasis on impact factor results from negative influence of neoliberal policies on academia claiming that what is needed is not just replacement of the impact factor with more sophisticated metrics for science publications but also discussion on the social value of research assessment and the growing precariousness of scientific careers in higher education.
Experts stress that there are limitations in using impact factors to evaluate a scholar's work. There are many reasons cited for not relying on impact factor alone to evaluate the output of a particular individual. Among these are the following:

  • A single factor is not sufficient for evaluating an author's work.
  • Journal values are meaningless unless compared within the same discipline. Impact factors vary among disciplines.
  • The impact factor was originally devised to show the impact of a specific journal, not a specific scholar. The quality and impact of the author's work may extend beyond the impact of a particular journal.
According to Jim Testa, a researcher for ThomsonReuters Scientific, the most widespread misuse of the Impact Factor is to evaluate the work of an individual author (instead of a journal). "To say that because a researcher is publishing in a certain journal, he or she is more influential or deserves more credit is not necessarily true. There are many other variables to consider." (interview 6/26/2008 in Thomson Reuters blog entry)

CNS Drugs
Journal Profile

About

CNS Drugs promotes rational pharmacotherapy within the disciplines of clinical psychiatry and neurology. The Journal includes:- Overviews of contentious or emerging issues.- Comprehensive narrative reviews that provide an authoritative source of information on pharmacological approaches to managing neurological and psychiatric illnesses.- Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.- Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in neurology and psychiatry.- Original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies.Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in CNS Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances. None

Highly Cited Keywords

ISSN
1172-7047
ISSN

The ISSN of CNS Drugs is 1172-7047 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

ISSN (Online)
1179-1934
ISSN (Online)

The ISSN (Online) of CNS Drugs is 1179-1934 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

Publisher
Adis International Ltd
Publisher

CNS Drugs is published by Adis International Ltd .

Publication Frequency
Monthly
Publication Frequency

CNS Drugs publishes reports Monthly .

Coverage
1994 - Present
Coverage

The Publication History of CNS Drugs covers 1994 - Present .

Open Access
NO
Open Access

CNS Drugs is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles. Anyone who wants to use the articles in any way must obtain permission from the publishers.

Publication Fee
Publication Fee

There is no publication fee for submiting manuscript to CNS Drugs. CNS Drugs is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles.

Language
English
Language

The language of CNS Drugs is English .

Country/Region
United Kingdom
Country/Region

The publisher of CNS Drugs is Adis International Ltd , which locates in United Kingdom .

Selected Articles

Full Title Authors
Full Title Authors
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms Maira Werneck · Guilherme Trevizan Kortas · Arthur Guerra de Andrade · João Mauricio Castaldelli-Maia · João Mauricio Castaldelli-Maia
Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions Andrew Naglich · Austin Lin · Sidarth Wakhlu · Bryon Adinoff · Bryon Adinoff
Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database Sophie Billioti de Gage · Cédric Collin · Thien Le-Tri · Antoine Pariente · Bernard Bégaud · Hélène Verdoux · Rosemary Dray-Spira · Mahmoud Zureik · Mahmoud Zureik
Effect of Statin Intensity on the Risk of Epilepsy After Ischaemic Stroke: Real-World Evidence from Population-Based Health Claims Fang Ju Lin · Hung‐Wei Lin · Yunn-Fang Ho · Yunn-Fang Ho
Treatment Strategies for Dravet Syndrome Kelly G. Knupp · Elaine C. Wirrell · Elaine C. Wirrell
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010 Simon Faissner · Ralf Gold · Ralf Gold
Perinatal Outcomes of Women Diagnosed with Attention-Deficit/Hyperactivity Disorder: An Australian Population-Based Cohort Study Alison Poulton · Alison Poulton · Bruce K. Armstrong · Bruce K. Armstrong · Ralph Nanan · Ralph Nanan
Adjunctive Eslicarbazepine Acetate in Pediatric Patients with Focal Epilepsy: A Systematic Review and Meta-Analysis Simona Lattanzi · Francesco Brigo · Elisabetta Grillo · Claudia Cagnetti · Alberto Verrotti · Gaetano Zaccara · Mauro Silvestrini · Mauro Silvestrini
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD) Tim Wigal · Jeffrey H. Newcorn · Nelson Handal · Sharon B. Wigal · Ioulietta Mulligan · Virginia Schmith · Eric Konofal · Eric Konofal
Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents Michael W. Jann · Scott R. Penzak · Scott R. Penzak
Assessing No Evidence of Disease Activity Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study Bianca Weinstock-Guttman · Jennie Medin · Nasreen Khan · Jonathan R. Korn · Ellen S. Lathi · Jason Silversteen · Jonathan Calkwood · Diego Silva · Robert Zivadinov · Robert Zivadinov
Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome Julio Quezada · Keith A. Coffman · Keith A. Coffman
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview Floriana De Angelis · D Plantone · D Plantone
Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence Anna K. Jönsson · Johan Schill · Hans Olsson · Olav Spigset · Staffan Hägg · Staffan Hägg
Author Correction to: l -Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain G. Cruccu · G. Di Stefano · F. Fattapposta · Stefano Jann · Luca Padua · Angelo Schenone · A. Truini · A. Truini
Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate David Coghill · David Coghill · Tobias Banaschewski · Caleb Bliss · Brigitte Robertson · Alessandro Zuddas · Alessandro Zuddas
Gadolinium-Based Contrast Agent-Related Toxicities Luca Pasquini · Antonio Napolitano · Emiliano Visconti · Daniela Longo · Andrea Romano · Paolo Tomà · Maria Camilla Rossi Espagnet · Maria Camilla Rossi Espagnet
Pharmacogenetics of Opioid Use Disorder Treatment Richard C. Crist · Toni-Kim Clarke · Wade H. Berrettini · Wade H. Berrettini
Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease Michele A. Faulkner · Michele A. Faulkner
Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies Katharina Stegmayer · Sebastian Walther · Peter N. van Harten · Peter N. van Harten
Convergent Mechanisms Underlying Rapid Antidepressant Action Panos Zanos · Scott M. Thompson · Ronald S. Duman · Carlos A. Zarate · Todd D. Gould · Todd D. Gould
Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment Claudio Solaro · Giulia Gamberini · Fabio Giuseppe Masuccio · Fabio Giuseppe Masuccio
Comment on:Activating Autophagy as a Therapeutic Strategy for Parkinsons Disease Juan Segura-Aguilar · Juan Segura-Aguilar
Authors Reply to Segura-Aguilar: Autophagosome maturation not autophagy induction is impaired in neurodegeneration Alan J. Fowler · Charbel E.-H. Moussa · Charbel E.-H. Moussa
Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review Antonios Douros · Antonios Douros · Antonios Douros · Matthew Ades · Christel Renoux · Christel Renoux · Christel Renoux
Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors Grainne M. O’Kane · Natasha B. Leighl · Natasha B. Leighl
Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinsons Disease Lawrence Elmer · Jorge L. Juncos · Carlos Singer · Daniel D. Truong · Susan R. Criswell · Sotirios A. Parashos · Larissa Felt · Reed Johnson · Rajiv Patni · Rajiv Patni
The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review Per Damkier · Per Damkier · Poul Videbech · Poul Videbech
Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: A multicentre, open-label, non-randomized, controlled trial H. Beurmanjer · Rama M. Kamal · Cor A.J. de Jong · B.A.G. Dijkstra · A.F.A. Schellekens · A.F.A. Schellekens
Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis Barbara Willekens · Nathalie Cools · Nathalie Cools
Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimers Disease Patricia del Cerro · Carolina Alquézar · Fernando Bartolomé · Fernando Bartolomé · Pedro González-Naranjo · Concepción Pérez · Eva Carro · Juan A. Páez · Nuria E. Campillo · Ángeles Martín-Requero · Ángeles Martín-Requero
Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review P. Molero · Josep Antoni Ramos-Quiroga · R. Martin-Santos · E. Calvo-Sánchez · L. Gutiérrez-Rojas · J. J. Meana · J. J. Meana
Role of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review MacKenzie R. Peltier · Mehmet Sofuoglu · Mehmet Sofuoglu
Polypharmacy Among Headache Patients: A Cross-Sectional Study Anna Ferrari · Carlo Baraldi · Manuela Licata · Cecilia Rustichelli · Cecilia Rustichelli
Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Tobias Banaschewski · Mats Johnson · Peter Nagy · Isabel Hernández Otero · Cesar A. Soutullo · Brian Yan · Alessandro Zuddas · David Coghill · David Coghill
Correction to: Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010 Simon Faissner · Ralf Gold · Ralf Gold
A Systematic Review and Meta-Analysis of the Risk of Dementia Associated with Benzodiazepine Use, After Controlling for Protopathic Bias Ross Penninkilampi · Ross Penninkilampi
Prescription of Zolpidem and the Risk of Fatal Motor Vehicle Collisions: A Population-Based, Case-Crossover Study from South Korea Bo Ram Yang · Ye-Jee Kim · Mi-Sook Kim · Sun-Young Jung · Nam-Kyong Choi · Byungkwan Hwang · Byung-Joo Park · Joongyub Lee · Joongyub Lee
Correction to: Gadolinium-Based Contrast Agent-Related Toxicities Luca Pasquini · Antonio Napolitano · Emiliano Visconti · Daniela Longo · Andrea Romano · Paolo Tomà · Maria Camilla Rossi Espagnet · Maria Camilla Rossi Espagnet
Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy Sheridan M. Hoy · Sheridan M. Hoy
The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing–Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study Robert Zivadinov · Eleonora Tavazzi · Jesper Hagemeier · Ellen Carl · David Hojnacki · Channa Kolb · Bianca Weinstock-Guttman · Bianca Weinstock-Guttman
Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents Michael W. Jann · Scott R. Penzak · Scott R. Penzak
MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study Ayman Tourbah · O. Gout · Alain Vighetto · Véronique Deburghgraeve · Jean Pelletier · Caroline Papeix · Christine Lebrun-Frenay · Pierre Labauge · David Brassat · Ahmed T. Toosy · David-Axel Laplaud · Olivier Outteryck · Thibault Moreau · Marc Debouverie · Pierre Clavelou · Olivier Heinzlef · Jérôme De Seze · Gilles Defer · Frédéric Sedel · Carl Arndt · Carl Arndt
Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration? Chiara Zecca · G. Bellavia · Laura Brambilla · L. P. Gutierrez · C. Gerardi · A. M. Fiori · L. R. Bernardini · G. Camera · Giulio Disanto · Liliane Petrini · J. Perugini · Carlo Antozzi · V. Torri Clerici · A. Bellino · Paolo Confalonieri · Claudio Gobbi · Renato Mantegazza · Silvia Rossi · Silvia Rossi
Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine Leda Pomes · Giovanna Gentile · Maurizio Simmaco · Marina Borro · Paolo Martelletti · Paolo Martelletti
Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis Bernard M. J. Uitdehaag · Bernard M. J. Uitdehaag
Newer Antiepileptic Drugs for Status Epilepticus in Adults: Whats the Evidence? Isabelle Beuchat · Jan Novy · Andrea O. Rossetti · Andrea O. Rossetti
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinsons Disease Lawrence Elmer · Jorge L. Juncos · Carlos Singer · Daniel D. Truong · Susan R. Criswell · Sotirios A. Parashos · Larissa Felt · Reed Johnson · Rajiv Patni · Rajiv Patni
Activating Autophagy as a Therapeutic Strategy for Parkinsons Disease Alan J. Fowler · Charbel E.-H. Moussa · Charbel E.-H. Moussa
An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis Caila B. Vaughn · Aisha Bushra · Channa Kolb · Bianca Weinstock-Guttman · Bianca Weinstock-Guttman
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain John Hey · Petr Kocis · Jakub Hort · Susan Abushakra · Aidan Power · Martin Vyhnalek · Jeremy Yu · Martin Tolar · Martin Tolar
Buprenorphine/Naloxone (Zubsolv®): A Review in Opioid Dependence Young-A Heo · Lesley J. Scott · Lesley J. Scott
Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders Michael J. Marmura · Aliza S. Kumpinsky · Aliza S. Kumpinsky
Drug Repurposing in Parkinsons Disease Dilan Athauda · Thomas Foltynie · Thomas Foltynie
Cladribine Tablets: A Review in Relapsing MS Emma D. Deeks · Emma D. Deeks
Correction to: Propofol: A Review of its Role in Pediatric Anesthesia and Sedation Vidya Chidambaran · Andrew J. Costandi · Ajay D’Mello · Ajay D’Mello
Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents Richard E. Frye · Richard E. Frye
Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis Dimitrios Papadopoulos · Dimos-Dimitrios Mitsikostas · Dimos-Dimitrios Mitsikostas
Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis Marita Zimmermann · Elizabeth Brouwer · Jeffrey A. Tice · Matt Seidner · Anne M. Loos · Shanshan Liu · Richard H. Chapman · Varun M. Kumar · Josh J. Carlson · Josh J. Carlson
Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis Mark Gudesblatt · Karl Wissemann · Myassar Zarif · Barbara Bumstead · Lori Fafard · Jeffrey Wilken · Karen Blitz · Marijean Buhse · Sourav Santra · Christophe Hotermans · Lily Lee · Lily Lee
Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs Christine Lebrun · Fanny Rocher · Fanny Rocher
Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox–Gastaut Syndrome: A Systematic Review and Meta-Analysis Simona Lattanzi · Francesco Brigo · Claudia Cagnetti · Eugen Trinka · Mauro Silvestrini · Mauro Silvestrini
Quantitative Pharmaco-Electroencephalography in Antiepileptic Drug Research Yvonne Höller · Christoph Helmstaedter · Klaus Lehnertz · Klaus Lehnertz
Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis Andrew Toyin Olagunju · Andrew Toyin Olagunju · Scott R. Clark · Bernhard T. Baune · Bernhard T. Baune · Bernhard T. Baune
Ocrelizumab: A Review in Multiple Sclerosis Yahiya Y. Syed · Yahiya Y. Syed
Emergency First-Line Anti-Seizure Medication for Seizures and Status Epilepticus: What is Going Wrong, Doctor? Raoul Sutter · Raoul Sutter
Ketamine for Refractory Status Epilepticus: A Systematic Review Anna Rosati · Salvatore De Masi · Renzo Guerrini · Renzo Guerrini
Recent Findings of the Comparative Efficacy and Tolerability of Antidepressants for Major Depressive Disorder: Do We Now Know What to Prescribe? Matthew V. Rudorfer · Matthew V. Rudorfer
Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis Pierre Ellul · Richard Delorme · Samuele Cortese · Samuele Cortese
Potential Role of Selective Serotonin Reuptake Inhibitors in Improving Functional Outcome after Stroke Janne Kaergaard Mortensen · Grethe Andersen · Grethe Andersen
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential Alexander Klistorner · Renew Mf-Vep Investigators · Yi Chai · Letizia Leocani · Philipp Albrecht · Orhan Aktas · Helmut Butzkueven · Tjalf Ziemssen · Focke Ziemssen · J. L. Frederiksen · Lei Xu · Diego Cadavid · Diego Cadavid
Palliative Sedation for the Terminally Ill Patient Ferdinando Garetto · Ferdinando Cancelli · Romina Rossi · Marco Maltoni · Marco Maltoni
The Cholinergic System as a Treatment Target for Opioid Use Disorder Kevin P. Jensen · Elise E. DeVito · Sarah Yip · Kathleen M. Carroll · Mehmet Sofuoglu · Mehmet Sofuoglu
From LBR-101 to Fremanezumab for Migraine Marcelo E. Bigal · Alan M. Rapoport · Stephen D. Silberstein · Sarah Walter · Richard J. Hargreaves · Ernesto Aycardi · Ernesto Aycardi
Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond Verena I. Leussink · Xavier Montalban · Hans-Peter Hartung · Hans-Peter Hartung
VMAT2 Inhibitors in Neuropsychiatric Disorders Arjun Tarakad · Joohi Jimenez-Shahed · Joohi Jimenez-Shahed
Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis Stefanie Kuerten · Leila Jackson · Joel Kaye · Timothy Vollmer · Timothy Vollmer
Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System Patrícia Schonhofen · Ivi Juliana Bristot · José Alexandre S. Crippa · Jaime Eduardo Cecílio Hallak · Antonio Waldo Zuardi · Richard B. Parsons · Fábio Klamt · Fábio Klamt
Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinsons Disease Julia Paik · Susan J. Keam · Susan J. Keam
Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review David D. Kim · Alasdair M. Barr · Yunsun Chung · Jessica W. Y. Yuen · Mahyar Etminan · Bruce Carleton · Randall F. White · William G. Honer · Ric M. Procyshyn · Ric M. Procyshyn
Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism Nikolaos Giagkou · Maria Stamelou · Maria Stamelou
Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial Jayashri Kulkarni · Natalie Thomas · Abdul Rahman Hudaib · Emorfia Gavrilidis · Jasmin Grigg · Raelene Ym Tan · Jacinta Cheng · Amelia Arnold · Caroline Gurvich · Caroline Gurvich
Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management Helia Ghanean · Amanda K. Ceniti · Amanda K. Ceniti · Sidney H. Kennedy · Sidney H. Kennedy
Botulinum Toxin: Does it have a Place in the Management of Depression? Matthew V. Rudorfer · Matthew V. Rudorfer
Prescribed Dose of Opioids and Overdose: A Systematic Review and Meta-Analysis of Unintentional Prescription Opioid Overdose Adeleke D. Adewumi · Samantha Hollingworth · Joemer Calderon Maravilla · Jason P. Connor · Rosa Alati · Rosa Alati
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention F. Markus Leweke · Juliane K. Mueller · Bettina Lange · Stefan Fritze · Cristina E. Topor · Dagmar Koethe · Cathrin Rohleder · Cathrin Rohleder
Nusinersen: A Review in 5q Spinal Muscular Atrophy Sheridan M. Hoy · Sheridan M. Hoy
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study Massimiliano Mirabella · Luca Prosperini · Matteo Lucchini · Laura Boffa · Giovanna Borriello · Maria Chiara Buscarinu · Diego Centonze · Antonio Cortese · Chiara De Fino · Laura De Giglio · Giorgia Elia · Roberta Fantozzi · Elisabetta Ferraro · Ada Francia · Simona Galgani · Claudio Gasperini · Shalom Haggiag · Doriana Landi · Girolama A. Marfia · Enrico Millefiorini · Fabrizia Monteleone · Viviana Nociti · Marco Salvetti · Eleonora Sgarlata · Carlo Pozzilli · Carlo Pozzilli
Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinsons Disease? Seok Jong Chung · Han Soo Yoo · Hye Sun Lee · Hyo Eun Jeong · Soo-Jong Kim · Jungsu S. Oh · Jae Seung Kim · Young H. Sohn · Phil Hyu Lee · Phil Hyu Lee
Correction to: Treatment Strategies for Dravet Syndrome Kelly G. Knupp · Elaine C. Wirrell · Elaine C. Wirrell
Use of Emergency Medication in Adult Patients with Epilepsy: A Multicentre Cohort Study from Germany Jeannette Kadel · Sebastian Bauer · Anke Hermsen · Ilka Immisch · Lara Kay · Karl Martin Klein · Susanne Knake · Katja Menzler · Philipp S. Reif · Felix Rosenow · Adam Strzelczyk · Adam Strzelczyk
Association Between Psychotropic Medication Polypharmacy and an Objective Measure of Balance Impairment Among Middle-Aged Adults: Results from the US National Health and Nutrition Examination Survey Natalie Bareis · Trisha A. Sando · Briana Mezuk · Steven A. Cohen · Steven A. Cohen
Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis Rosa Camila Lucchetta · Fernanda S. Tonin · Hh Borba · Letícia Paula Leonart · Vinicius Lins Ferreira · Aline F. Bonetti · Bruno Salgado Riveros · Jefferson Becker · Roberto Pontarolo · Fernando Fernandez-Llimos · Astrid Wiens · Astrid Wiens
Assessment and Management of Neuropsychiatric Symptoms in Parkinsons Disease Christoph Mueller · Anto P. Rajkumar · Yi Min Wan · Latha Velayudhan · Dominic H. ffytche · Kallol Ray Chaudhuri · Dag Aarsland · Dag Aarsland
ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability Yuval Ramot · Abraham Nyska · Liat Adar · Cecile Durlach · Danny Fishelovitch · Giuseppe Sacco · Rosa Anna Manno · Sheila Oren · Itay Perlstein · Oron Yacobi-Zeevi · Oron Yacobi-Zeevi
Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data Mats O. Magnusson · Mahesh N. Samtani · Elodie L. Plan · E. Niclas Jonsson · Stefaan Rossenu · An Vermeulen · Alberto Russu · Alberto Russu
Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard? David Taylor · David Taylor
Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents Morten Blinkenberg · Per Soelberg Sørensen · Per Soelberg Sørensen
Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine Leonie Hennissen · Mireille J. Bakker · Tobias Banaschewski · Sara Carucci · David Coghill · David Coghill · Marina Danckaerts · Ralf W. Dittmann · Chris Hollis · Hanna Kovshoff · Suzanne McCarthy · Peter Nagy · Edmund Sonuga-Barke · Ian C. K. Wong · Ian C. K. Wong · Alessandro Zuddas · Eric Rosenthal · Jan K. Buitelaar · Jan K. Buitelaar
Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis Nicola De Stefano · Diego G. Silva · Michael Barnett · Michael Barnett
Do Statins Have Antidepressant Effects Ole Köhler-Forsberg · Ole Köhler-Forsberg · Ole Köhler-Forsberg · Christiane Gasse · Christiane Gasse · Michael Berk · Søren Dinesen Østergaard · Søren Dinesen Østergaard · Søren Dinesen Østergaard
A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics Yawen Jiang · Jeffrey S. McCombs · Susie H. Park · Susie H. Park
Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets David S. Baldwin · David S. Baldwin · David S. Baldwin · Ruihua Hou · Robert Gordon · Nathan T. M. Huneke · Matthew Garner · Matthew Garner
Statin Adherence and the Risk of Stroke: A Dose-Response Meta-Analysis Tao Xu · Xinyuan Yu · Shu Ou · Xi Liu · Jinxian Yuan · Yangmei Chen · Yangmei Chen
Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants R. Belzeaux · Rixing Lin · Gustavo Turecki · Gustavo Turecki
A Focused Systematic Review of Pharmacological Treatment for Borderline Personality Disorder Ella Hancock-Johnson · Chris Griffiths · Marco Picchioni · Marco Picchioni
Antimicrobial Use in Patients with Dementia: Current Concerns and Future Recommendations Carole Parsons · Jenny T. van der Steen · Jenny T. van der Steen · Jenny T. van der Steen
Newer Antiepileptic Drugs in Status Epilepticus: Prescription Trends and Outcomes in Comparison with Traditional Agents Isabelle Beuchat · Jan Novy · Andrea O. Rossetti · Andrea O. Rossetti
Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam? Elyse Swallow · Anna Fang · James Signorovitch · Jonathan Plumb · Simon Borghs · Simon Borghs
Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study Robert L. Smith · Tore Haslemo · Ole A. Andreassen · Erik Eliasson · Marja-Liisa Dahl · Olav Spigset · Espen Molden · Espen Molden
Drug Safety Analysis in a Real-Life Cohort of Parkinsons Disease Patients with Polypharmacy Saskia Müller-Rebstein · Saskia Müller-Rebstein · Claudia Trenkwalder · Jens Ebentheuer · Wolfgang H. Oertel · Carsten Culmsee · Günter U. Höglinger · Günter U. Höglinger · Günter U. Höglinger
l-Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain G. Cruccu · G. Di Stefano · F. Fattaposta · Stefano Jann · Luca Padua · Angelo Schenone · A. Truini · A. Truini
Targeting Neuroinflammation to Treat Alzheimers Disease A. Ardura-Fabregat · Erik Boddeke · A. Boza-Serrano · S. Brioschi · S. Castro-Gomez · K. Ceyzériat · K. Ceyzériat · C. Dansokho · T. Dierkes · T. Dierkes · G. Gelders · Michael T. Heneka · Michael T. Heneka · Lianne Hoeijmakers · A. Hoffmann · L. Iaccarino · S. Jahnert · K. Kuhbandner · G. Landreth · N. Lonnemann · P. A. Löschmann · R. M. McManus · A. Paulus · K. Reemst · J. M. Sanchez-Caro · A. Tiberi · A. van der Perren · A. Vautheny · A. Vautheny · Carmen Venegas · A. Webers · Patrick Weydt · Teodora Stella Wijasa · X. Xiang · Y. Yang · Y. Yang
Effectiveness of pharmacological treatment for attention deficit/hyperactivity disorder on physical injuries: A systematic review and meta-analysis of observational studies Kenneth K. C. Man · Kenneth K. C. Man · Kenneth K. C. Man · Patrick Ip · Esther W. Chan · Siew-ling Law · Miriam T. Y. Leung · Evelyn X. Y. Ma · Wan-ting Quek · Ian C. K. Wong · Ian C. K. Wong · Ian C. K. Wong
Outcome Measures in Clinical Trials for Multiple Sclerosis Caspar E.P. van Munster · Bernard M. J. Uitdehaag · Bernard M. J. Uitdehaag
Dispensability of Annual Laboratory Follow-Up After More than 2 Years of Valproic Acid Use: A Systematic Review Rosanne W. Meijboom · Koen P. Grootens · Koen P. Grootens
Comparing Safety and Efficacy ofThird-GenerationAntiepileptic Drugs: Long-Term Extension and Post-marketing Treatment Charlotte S. Kwok · Emily L. Johnson · Gregory L. Krauss · Gregory L. Krauss
Clozapine and Gastrointestinal Hypomotility Dan Cohen · Dan Cohen
Lisdexamfetamine: A Review in Binge Eating Disorder Young-A Heo · Sean T. Duggan · Sean T. Duggan
Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases Ana B. Ramos-Hryb · Francis L. Pazini · Manuella P. Kaster · Ana Lúcia S. Rodrigues · Ana Lúcia S. Rodrigues
Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review Mohammad Hosein Farzaei · Zahra Shahpiri · Zahra Shahpiri · Roodabeh Bahramsoltani · Roodabeh Bahramsoltani · Marjan Moghaddam nia · Marjan Moghaddam nia · Fariba Najafi · Roja Rahimi · Roja Rahimi · Roja Rahimi
The Role of GABA Receptor Agonists in Anesthesia and Sedation Janette Brohan · Basavana Gouda Goudra · Basavana Gouda Goudra
Granulocyte Colony-Stimulating Factor (G-CSF) for the Treatment of Spinal Cord Injury MirHojjat Khorasanizadeh · Mahsa Eskian · Alexander R. Vaccaro · Vafa Rahimi-Movaghar · Vafa Rahimi-Movaghar
Do Pharmaceuticals Improve Driving in Individuals with ADHD? A Review of the Literature and Evidence for Clinical Practice Craig B. H. Surman · Ronna Fried · Lauren Rhodewalt · Heidi Boland · Heidi Boland
Pharmacotherapy of Cardiovascular Autonomic Dysfunction in Parkinson Disease Cyndya Shibao · Horacio Kaufmann · Horacio Kaufmann
Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder Jeffrey H. Newcorn · Peter Nagy · Ann Childress · Glen Frick · Brian Yan · Steven R. Pliszka · Steven R. Pliszka
Selecting Rational Drug Combinations in Epilepsy Bassel Abou-Khalil · Bassel Abou-Khalil
Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany Brendan J. Snellgrove · Tilman Steinert · Susanne Jaeger · Susanne Jaeger
Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment Lucie Barateau · Roland S. Liblau · Christelle Peyron · Yves Dauvilliers · Yves Dauvilliers
Binge Drinking: Current Diagnostic and Therapeutic Issues Benjamin Rolland · Mickaël Naassila · Mickaël Naassila
New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability Samuele Cortese · Samuele Cortese · Giulia D’Acunto · Eric Konofal · Gabriele Masi · Benedetto Vitiello · Benedetto Vitiello
Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations Corinne Cather · Gladys N. Pachas · Kristina M. Cieslak · A. Eden Evins · A. Eden Evins
Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open label randomized controlled trial Paola Bozzatello · Paola Rocca · Maria Uscinska · Silvio Bellino · Silvio Bellino
Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study Richard H. Weisler · Richard H. Weisler · Michael Greenbaum · Valerie Arnold · Ming Yu · Brian Yan · Margo Jaffee · Brigitte Robertson · Brigitte Robertson
New, Occasional, and Frequent Use of Zolpidem or Zopiclone (Alone and in Combination) and the Risk of Injurious Road Traffic Crashes in Older Adult Drivers: A Population-Based Case–Control and Case-Crossover Study Alicia Nevriana · Jette Möller · Lucie Laflamme · Joel Monárrez-Espino · Joel Monárrez-Espino
Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe David Coghill · David Coghill · Tobias Banaschewski · Peter Nagy · Isabel Hernández Otero · Cesar A. Soutullo · Brian Yan · Beatriz Caballero · Alessandro Zuddas · Alessandro Zuddas
Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study Srihari Gopal · Rosanne Lane · Isaac Nuamah · Margaret Copenhaver · Jaskaran Singh · David Hough · Mark Bach · Adam Savitz · Adam Savitz
Pharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder Andrew Naglich · Bryon Adinoff · E. Sherwood Brown · E. Sherwood Brown
Therapeutic Potential of Baicalein in Alzheimers Disease and Parkinsons Disease Yanwei Li · Jinying Zhao · Christian Hölscher · Christian Hölscher
Dopaminergic Therapies for Non-motor Symptoms in Parkinsons Disease Eva Schaeffer · Daniela Berg · Daniela Berg
Erratum to: Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs Peter Joseph Jongen · Peter Joseph Jongen
Clozapine-Induced Gastrointestinal Hypomotility: A 22-Year Bi-National Pharmacovigilance Study of Serious or Fatal Slow Gut Reactions, and Comparison with International Drug Safety Advice Susanna Every-Palmer · Pete M. Ellis · Pete M. Ellis
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model Marjie L. Hard · Richard Mills · Brian M. Sadler · Angela Y. Wehr · Peter J. Weiden · Lisa von Moltke · Lisa von Moltke
Ascorbic Acid to Manage Psychiatric Disorders Morgana Moretti · Daiane B. Fraga · Ana Lúcia S. Rodrigues · Ana Lúcia S. Rodrigues
A Review of Adjunctive CNS Medications Used for the Treatment of Post-Surgical Pain Ajit S. Rai · Howard Meng · Howard Meng · Aliza Z Weinrib · Aliza Z Weinrib · Aliza Z Weinrib · Marina Englesakis · Dinesh Kumbhare · Liza Grosman-Rimon · Joel Katz · Joel Katz · Joel Katz · Hance Clarke · Hance Clarke · Hance Clarke
Cariprazine: A Review in Schizophrenia Karly P. Garnock-Jones · Karly P. Garnock-Jones
The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimers Disease, Based on a Mechanistic Target of Rapamycin Pathway Lin Li · Lin Li
Sodium Channel Blockers in the Treatment of Epilepsy Martin J. Brodie · Martin J. Brodie
Impact of Muscarinic M3 Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study Yen-Hao Tran · Catharina C.M. Schuiling-Veninga · Jorieke E. H. Bergman · Henk Groen · Bob Wilffert · Bob Wilffert
Managing Negative Symptoms of Schizophrenia: How Far Have We Come? Joshua T. Kantrowitz · Joshua T. Kantrowitz · Joshua T. Kantrowitz
Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis Gali Pariente · Tom Leibson · Talya Shulman · Thomasin Adams-Webber · Eran Barzilay · Irena Nulman · Irena Nulman
Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine Peer Tfelt-Hansen · Frederik Nybye Ågesen · Agniezka Pavbro · Jacob Tfelt-Hansen · Jacob Tfelt-Hansen
Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimers Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data Petr Kocis · Martin Tolar · Jeremy Yu · William Sinko · Soumya S. Ray · Kaj Blennow · Howard Fillit · Howard Fillit · John Hey · John Hey
Stiripentol in the Management of Epilepsy Katherine C. Nickels · Elaine C. Wirrell · Elaine C. Wirrell
Cell Therapy for Multiple Sclerosis Pamela Sarkar · Claire M Rice · Neil Scolding · Neil Scolding
Psychopharmacology in the Age ofBig Data: The Promises and Limitations of Electronic Prescription Records Matthew V. Rudorfer · Matthew V. Rudorfer
Erratum to: Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD) Katelyn R. Keyloun · Ryan N. Hansen · Zsolt Hepp · Patrick Gillard · Michael E. Thase · Emily Beth Devine · Emily Beth Devine
Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain Mayur M. Patel · Bhoomika M. Patel · Bhoomika M. Patel
Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension Jacquie Baker · Jacquie Baker · Kurt Kimpinski · Kurt Kimpinski · Kurt Kimpinski
Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts Enrico Franceschi · Santino Minichillo · Alba A. Brandes · Alba A. Brandes
Pharmacological Management of Bipolar Disorder in Pregnancy Sarah Jones · Ian Richard Jones · Ian Richard Jones
Anesthetics and Outcome in Status Epilepticus: A Matched Two-Center Cohort Study Raoul Sutter · Raoul Sutter · Gian Marco De Marchis · Saskia Semmlack · Peter Fuhr · Stephan Rüegg · Stephan Marsch · Wendy C. Ziai · Peter W. Kaplan · Peter W. Kaplan
Safinamide: A Review in Parkinsons Disease Hannah A. Blair · Sohita Dhillon · Sohita Dhillon
Benzodiazepine Use and Risk of Developing Alzheimers Disease: A Case-Control Study Based on Swiss Claims Data Fabienne A. Biétry · Alena M. Pfeil · Oliver Reich · Matthias Schwenkglenks · Christoph R. Meier · Christoph R. Meier
Nogo-A Antibodies for Progressive Multiple Sclerosis Benjamin V. Ineichen · Benjamin V. Ineichen · Patricia S. Plattner · Patricia S. Plattner · Nicolas Good · Nicolas Good · Roland Martin · Michael Linnebank · Michael Linnebank · Martin E. Schwab · Martin E. Schwab · Martin E. Schwab
Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal Steven J. Weintraub · Steven J. Weintraub
Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinicians Overview Martin J. Brodie · Martin J. Brodie
Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention Rama M. Kamal · Martijn S. van Noorden · Wim Wannet · H. Beurmanjer · B.A.G. Dijkstra · A.F.A. Schellekens · A.F.A. Schellekens
Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial Laura De Giglio · Fabiana Marinelli · Valeria Barletta · Veronica A. Pagano · Floriana De Angelis · Fulvia Fanelli · Nikolaos Petsas · Patrizia Pantano · Valentina Tomassini · Carlo Pozzilli · Carlo Pozzilli
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise Manfred Westphal · Cecile L. Maire · Katrin Lamszus · Katrin Lamszus
New Non-Intravenous Routes for Benzodiazepines in Epilepsy: A Clinician Perspective Marco Mula · Marco Mula · Marco Mula
Serotonin 5-HT6 Receptor Antagonists in Alzheimers Disease: Therapeutic Rationale and Current Development Status Hilda Ferrero · Maite Solas · Paul T. Francis · Maria J. Ramirez · Maria J. Ramirez
Targeting Functional Impairments in the Treatment of Children and Adolescents with ADHD Tyler Sasser · Erin N. Schoenfelder · Mark A. Stein · Mark A. Stein
Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management Kathlyn J. Ronaldson · Kathlyn J. Ronaldson
Pharmacotherapy for Vascular Cognitive Impairment Muhammad U. Farooq · Jiang-Yong Min · Christopher Goshgarian · Philip B. Gorelick · Philip B. Gorelick
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts Thomas Berger · Irina Elovaara · S. Fredrikson · Chris McGuigan · Lucia Moiola · Kjell-Morten Myhr · Celia Oreja-Guevara · Igor Stoliarov · Uwe K. Zettl · Uwe K. Zettl
The Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study Susanna Every-Palmer · Pete M. Ellis · Mike Nowitz · James Stanley · Eve Grant · Mark Huthwaite · Helen Dunn · Helen Dunn
Impact of Drug Manipulation on Seizure Freedom in Adults with Uncontrolled Epilepsy: A Prospective Controlled Study in Rural China Xiaoting Hao · Ziyi Chen · Bo Yan · Patrick Kwan · Patrick Kwan · Patrick Kwan · Dong Zhou · Dong Zhou
Therapeutic Potential of Transdermal Glyceryl Trinitrate in the Management of Acute Stroke Jason P. Appleton · Nikola Sprigg · Philip M.W. Bath · Philip M.W. Bath
Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence Slaven Pikija · Laszlo K. Sztriha · J. Sebastian Mutzenbach · Stefan Golaszewski · Johann Sellner · Johann Sellner
Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis Diane Moujalled · Anthony R. White · Anthony R. White
The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective Thor-Henrik Brodtkorb · Melissa Bell · Adam Irving · Philippe Laramée · Philippe Laramée
Potential of Oxytocin in the Treatment of Schizophrenia Paul D. Shilling · David Feifel · David Feifel
Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities Nicola Logallo · Nicola Logallo · Christopher Elnan Kvistad · Christopher Elnan Kvistad · Aliona Nacu · Aliona Nacu · Lars Thomassen · Lars Thomassen · Lars Thomassen
Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion Aaron M. Cook · Muhammad S. Zafar · Sally Mathias · Alejandra M. Stewart · Ana C. Albuja · Meriem Bensalem-Owen · Siddharth Kapoor · Robert J. Baumann · Robert J. Baumann
Managing an Unprovoked First Seizure in Adults David Gloss · Allan Krumholz · Allan Krumholz
Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis Shumita Roy · Ralph H. B. Benedict · Allison Drake · Bianca Weinstock-Guttman · Bianca Weinstock-Guttman
Cutaneous Adverse Effects of Neurologic Medications Eman Bahrani · Chloe E. Nunneley · Sylvia Hsu · Sylvia Hsu
Worldwide Differences in Regulations of Clozapine Use Jimmi Nielsen · Corina Young · Petru Ifteni · Taishiro Kishimoto · Yu Tao Xiang · Peter F J Schulte · Christoph U. Correll · David Taylor · David Taylor
Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients Gabriel Perlemuter · Patrice Cacoub · Dominique Valla · Dominique Valla · Dominique Guyader · Barbara Saba · Cécile Batailler · Kevin Moore · Kevin Moore
Adjunctive Brexpiprazole: A Review in Major Depressive Disorder Kate McKeage · Kate McKeage
A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study Peter J. Weiden · Raymond Manning · Curt D. Wolfgang · J. Michael Ryan · Linda Mancione · Guangyang Han · Saeed Ahmed · Mallery G. Mayo · Mallery G. Mayo
Naltrexone: A Pan-Addiction Treatment? Elias Aboujaoude · Wael Salame · Wael Salame
Secondary Progressive Multiple Sclerosis: Definition and Measurement D Plantone · Floriana De Angelis · Anisha Doshi · Anisha Doshi
Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date Vladimir Lerner · Peter McCaffery · Michael S. Ritsner · Michael S. Ritsner
Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date Mary R. Lee · Matthew C.H. Rohn · Gianluigi Tanda · Lorenzo Leggio · Lorenzo Leggio · Lorenzo Leggio
Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia Thomas W. Weickert · Thomas W. Weickert · Katherine M. Allen · Katherine M. Allen · Cynthia Shannon Weickert · Cynthia Shannon Weickert · Cynthia Shannon Weickert
A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia Rebecca C. Harvey · Anthony C. James · Gemma E. Shields · Gemma E. Shields
Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals Gillian M. Keating · Gillian M. Keating
Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity Mark Zimmerman · Matthew D. Multach · Emily Walsh · Lia K. Rosenstein · Douglas Gazarian · Heather L. Clark · Heather L. Clark
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis Samuel F. Hunter · James D. Bowen · Anthony T. Reder · Anthony T. Reder
Treatment Options for Narcolepsy Lucie Barateau · Régis Lopez · Yves Dauvilliers · Yves Dauvilliers
Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence Sura Alwan · Jan M. Friedman · Christina D. Chambers · Christina D. Chambers
The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review Thomas M. Gates · Lucette A. Cysique · Lucette A. Cysique · Lucette A. Cysique
Abuse Potential of Pregabalin: a Systematic Review Ole Schjerning · Mary Rosenzweig · Anton Pottegård · Per Damkier · Per Damkier · Jimmi Nielsen · Jimmi Nielsen
Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis Andrew T. Chan · Jérôme De Seze · Manuel Comabella · Manuel Comabella
Unexplained Painful Physical Symptoms in Patients with Major Depressive Disorder: Prevalence, Pathophysiology and Management Jan Jaracz · Karolina Gattner · Krystyna Jaracz · Krystyna Górna · Krystyna Górna
Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database Chris Bushe · Esther Sobanski · David Coghill · Lovisa Berggren · Katrien De Bruyckere · Sami Leppämäki · Sami Leppämäki · Sami Leppämäki
Brexpiprazole: A Review in Schizophrenia Karly P. Garnock-Jones · Karly P. Garnock-Jones
Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease Santiago Perez-Lloret · Olivier Rascol · Olivier Rascol · Olivier Rascol
Ghost-Pill-Buster: A Case Study of Intact Levetiracetam Extended-Release Tablets after Dissolution Testing Dajun Sun · Hong Wen · Anna Externbrink · Zongming Gao · David A. Keire · Gregory L. Krauss · Wenlei Jiang · Wenlei Jiang
Lisdexamfetamine: A Review in ADHD in Adults James E. Frampton · James E. Frampton
The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials Neal Hermanowicz · Aaron Ellenbogen · Gordon A. Irving · Mark J. Buchfuhrer · Mark J. Jaros · Gwendoline Shang · Richard Kim · Richard Kim
A Review of Pharmacologic Treatment for Compulsive Buying Disorder Célia Soares · Natália Fernandes · Pedro Morgado · Pedro Morgado
The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects Guido K. Frank · Guido K. Frank · Megan E. Shott · Megan E. Shott
The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome Alon Y. Avidan · Daniel Lee · Margaret Park · Mark J. Jaros · Gwendoline Shang · Richard Kim · Richard Kim
Erratum to: Targeting CGRP: A New Era for Migraine Treatment Stephanie Wrobel Goldberg · Stephen D. Silberstein · Stephen D. Silberstein
Levodopa–Carbidopa Intestinal Gel in Patients with Parkinsons Disease: A Systematic Review Karin Wirdefeldt · Per Odin · Dag Nyholm · Dag Nyholm
The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Vanessa C. Evans · Golnoush Alamian · Jane McLeod · Cindy Woo · Lakshmi N. Yatham · Raymond W. Lam · Raymond W. Lam
Perispinal Delivery of CNS Drugs Edward Tobinick · Edward Tobinick
Asenapine: A Review in Schizophrenia Greg L. Plosker · Emma D. Deeks · Emma D. Deeks
Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia Mohammad M. Khan · Mohammad M. Khan
May the Force Be With You: The Light and Dark Sides of the Microbiota–Gut–Brain Axis in Neuropsychiatry Eoin Sherwin · Kiran V. Sandhu · Timothy G. Dinan · John F. Cryan · John F. Cryan
Comment on:Levodopa-Carbidopa Intestinal Gel in Patients with Parkinsons Disease: A Systematic Review Andrew T. Lambarth · Andrew T. Lambarth
Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding Gin S. Malhi · Gin S. Malhi · Tim Outhred · Tim Outhred · Tim Outhred
A Review of Treatment Options for Progressive Supranuclear Palsy Maria Stamelou · Günter U. Höglinger · Günter U. Höglinger · Günter U. Höglinger
Topiramate Extended Release: A Review in Epilepsy Sheridan M. Hoy · Sheridan M. Hoy
Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials Jie Zhang · Ruili Wei · Zhongqin Chen · Benyan Luo · Benyan Luo
Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database K. De Bruyckere · Chris Bushe · C. Bartel · Lovisa Berggren · Cornelis C. Kan · Ralf W. Dittmann · Ralf W. Dittmann
Valproate-Associated Parkinsonism: A Critical Review of the Literature Florian Brugger · Florian Brugger · Kailash P. Bhatia · Frank M. C. Besag · Frank M. C. Besag
The Clinical Applications of Extended-Release Abuse-Deterrent Opioids Nalini Vadivelu · Erika Schermer · Gopal Kodumudi · Jack M. Berger · Jack M. Berger
Improving Memory and Cognition in Individuals with Down Syndrome Michael S. Rafii · Michael S. Rafii · Michael S. Rafii
Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimers Disease: A Systematic Review and Meta-Analysis Tingting Xiao · Bin Jiao · Weiwei Zhang · Beisha Tang · Lu Shen · Lu Shen
Pharmacogenetics and Imaging–Pharmacogenetics of Antidepressant Response: Towards Translational Strategies Tristram A. Lett · Henrik Walter · Eva J. Brandl · Eva J. Brandl
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond Wolfgang Löscher · Michel Gillard · Zara A. Sands · Rafal M. Kaminski · Henrik Klitgaard · Henrik Klitgaard
Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications Melinda Liu · Yuan Yu M. Huang · Sylvia Hsu · Sylvia Hsu
Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review Rainer Freynhagen · Miroslav Backonja · Stephan A. Schug · Gavin Lyndon · Bruce Parsons · Stephen Watt · Regina Behar · Regina Behar
Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinsons Disease: Therapeutic Rationale and Current Status Tara Swart · Michael J. Hurley · Michael J. Hurley
B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence Silke Kinzel · Martin Weber · Martin Weber · Martin Weber
Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China Yingying Su · Gang Liu · Fei Tian · Ren G · Mengdi Jiang · Chun B · Yunzhou Zhang · Hong Ye · Daiquan Gao · Weibi Chen · Weibi Chen
Novel Levodopa Formulations for Parkinsons Disease Maria Eliza Freitas · Marta Ruiz-Lopez · Susan H. Fox · Susan H. Fox
Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation Ian Wadsworth · Thomas Jaki · Graeme J. Sills · Richard Appleton · J. Helen Cross · Anthony G Marson · Anthony G Marson · Timothy Martland · Ailsa McLellan · Philip E. M. Smith · John M. Pellock · Lisa Hampson · Lisa Hampson
Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials Kim S. J. Lao · Y He · Ian C. K. Wong · Ian C. K. Wong · Frank M. C. Besag · Frank M. C. Besag · Esther W. Chan · Esther W. Chan
Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis Chiara Bernagie · Marina Danckaerts · M. Wampers · Marc De Hert · Marc De Hert
A cost-utility analysis of lisdexamfetamine versus atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and inadequate response to methylphenidate: Evelina A. Zimovetz · Stephen M. Beard · Paul Hodgkins · Matthias Bischof · Josephine Mauskopf · Juliana Setyawan · Juliana Setyawan
Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension Wolfgang H. Oertel · Gerda M. Saletu-Zyhlarz · Michael Hopp · Björn Bosse · Claudia Trenkwalder · Claudia Trenkwalder
Pharmacologic Neuroprotection for Functional Outcomes After Traumatic Brain Injury: A Systematic Review of the Clinical Literature Shaun E. Gruenbaum · Alexander Zlotnik · Benjamin F. Gruenbaum · Denise Hersey · Federico Bilotta · Federico Bilotta
Therapeutic Potential of Genipin in Central Neurodegenerative Diseases Yanwei Li · Lin Li · Christian Hölscher · Christian Hölscher · Christian Hölscher
Apolipoprotein E as a Therapeutic Target in Alzheimers Disease: A Review of Basic Research and Clinical Evidence Yu Yamazaki · Meghan M. Painter · Guojun Bu · Takahisa Kanekiyo · Takahisa Kanekiyo
The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study Janet Sultana · Janet Sultana · Andrea Fontana · Francesco Giorgianni · Alessandro Pasqua · Claudio Cricelli · Edoardo Spina · Giovanni Gambassi · Jelena Ivanovic · Carmen Ferrajolo · Carmen Ferrajolo · Mariam Molokhia · Clive Ballard · Samantha Sharp · Miriam Sturkenboom · Gianluca Trifirò · Gianluca Trifirò · Gianluca Trifirò
Levetiracetam Versus Phenytoin for Seizure Prophylaxis Following Traumatic Brain Injury: A Systematic Review and Meta-Analysis Yong Yang · Fangshuo Zheng · Xin Xu · Xuefeng Wang · Xuefeng Wang
Carbidopa/Levodopa ER Capsules (Rytary®, Numient™): A Review in Parkinsons Disease Sarah L. Greig · Kate McKeage · Kate McKeage
New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What has been Investigated and What is in the Pipeline? Emma Beard · Lion Shahab · Damian M. Cummings · Susan Michie · Robert West · Robert West
Aβ-Degrading Proteases: Therapeutic Potential in Alzheimer Disease Malcolm A. Leissring · Malcolm A. Leissring
Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study Alp Üçok · Uğur Çıkrıkçılı · Ceylan Ergül · Öznur Tabak · Ada Salaj · Sercan Karabulut · Christoph U. Correll · Christoph U. Correll
Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management Fang Fang · Hongwei Sun · Zuowei Wang · Ming Ren · Joseph R. Calabrese · Keming Gao · Keming Gao
Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia Eduard Parellada · Miquel Bioque · Miquel Bioque
Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy Sheridan M. Hoy · Sheridan M. Hoy
(S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study Julia Höfler · Alexandra Rohracher · Gudrun Kalss · Georg Zimmermann · Judith Dobesberger · Georg Pilz · Markus Leitinger · Giorgi Kuchukhidze · Giorgi Kuchukhidze · Kevin Butz · Alexandra Taylor · Helmut F. Novak · Eugen Trinka · Eugen Trinka
Treatment for Rheumatoid Arthritis and Risk of Alzheimers Disease: A Nested Case-Control Analysis Richard C. Chou · Richard C. Chou · Michael F. Kane · Sanjay Ghimire · Shiva Gautam · Shiva Gautam · Jiang Gui · Jiang Gui · Jiang Gui
Newly Approved Agents for the Treatment and Prevention of Pediatric Migraine Joanne Kacperski · Joanne Kacperski · Andrew D. Hershey · Andrew D. Hershey · Andrew D. Hershey
Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review Jennifer B. Levin · Anna Krivenko · Anna Krivenko · Molly Howland · Rebecca Schlachet · Martha Sajatovic · Martha Sajatovic
The Benzodiazepine–Dementia Disorders Link: Current State of Knowledge Antoine Pariente · Sophie Billioti de Gage · Nicholas Moore · Bernard Bégaud · Bernard Bégaud

A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms
CNS Drugs | 2018
Maira Werneck · Guilherme Trevizan Kortas · Arthur Guerra de Andrade · João Mauricio Castaldelli-Maia · João Mauricio Castaldelli-Maia
Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database
CNS Drugs | 2018
Sophie Billioti de Gage · Cédric Collin · Thien Le-Tri · Antoine Pariente · Bernard Bégaud · Hélène Verdoux · Rosemary Dray-Spira · Mahmoud Zureik · Mahmoud Zureik
Treatment Strategies for Dravet Syndrome
CNS Drugs | 2018
Kelly G. Knupp · Elaine C. Wirrell · Elaine C. Wirrell